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1997 with at least one ICD-9 code of ischemic heart
disease or heart failure in 1996 were included. From this
cohort all patients with AF (ICD-9 427.31) were identi-
ﬁed and two non-AF controls were randomly selected for
each case. Resource use and charges were compared using
univariate tests. Logistic and log-linear regression tech-
niques were also used for risk-adjustment.
RESULTS: 3.3% of AF-patients (n = 831) and 2.5% of
non-AF patients (n = 1662) had a cerebrovascular event
in 1997. One-year median resource use in the AF and
non-AF group was as follows: hospital days: 7.0 vs. 6.0;
outpatient visits: 8.0 vs. 6.0; home health visits: 6.0 vs.
5.0; ER visits: 1.0 vs. 1.0, nursing home days: 7.5 vs. 6.0.
The median annual total charges per AF patient and non-
AF patient were $22,213 and $17,472, respectively. On
controlling for age, gender, Charlson Comorbidity Index,
type of CVD, and prior year’s hospital use, the two
groups only differed signiﬁcantly in number of outpatient
visits. No differences in costs existed.
CONCLUSIONS: AF patient had a higher utilization of
outpatient visits as compared to non-AF patients. It is
possible that presence of severe underlying CVD in both
groups overwhelms the differences in the costs attribut-
able only to AF. Further examination of the pharmacy
data will help reveal any differences in drug utilization
and costs due to AF.
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OBJECTIVES: Given the high hospitalization rate asso-
ciated with congestive heart failure (CHF), the objective
of this analysis is to assess hospital resource utilization of
CHF patients treated with inotropic agents, diuretics or
both. 
METHODS: Patients hospitalized with a primary dis-
charge CHF diagnosis between July 2000 and June 2001
were identiﬁed from a hospital-based, service-level 
database of 217 health care facilities. Patients managed
with diuretic and/or inotropic drugs were segmented into
the following treatment groups: inotropics only, diuretics
only (IV, oral or both), and inotropics with diuretics (IV,
oral or both). Drug treatment, hospital unit care patterns,
and incurred mean total hospital and drug costs were
determined for each treatment group.
RESULTS: From the patient sample (N = 58,131), 53%
were treated with IV and oral diuretic therapy, 20% with
IV-only diuretics, and 14% with inotropics plus IV and
oral diuretics. Length of stay (LOS) ranged from 4 to 9
days, with intensive care unit (ICU) or subacute stepdown
unit LOS accounting for 3–6 days and inotropic-treated
cases having longer stays. Inotropic therapy was usually
initiated during the ﬁrst or second day of hospitalization.
One-third of patients treated with inotropic drugs were
transferred to the ICU during the ﬁrst hospital day while
one-third of diuretic treated cases received stepdown care.
Patients who received inotropic therapy with oral and IV
diuretics had the highest total hospital and drug costs 
at $12,461 and $382, respectively. Patients in the oral
diuretic-only treatment group had the lowest total costs
($4,380). Most patients were discharged home but more
inotropic patients expired in-hospital (4–15%) while
more diuretic cases were transferred to a skilled nursing
facility (10–12%).
CONCLUSIONS: CHF cases treated with inotropic drugs
had longer overall and ICU LOS, higher hospital costs
and in-hospital mortality when compared to diuretic-only
treated patients.
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OBJECTIVE: Clinical trials have demonstrated the safety
and efﬁcacy of prophylaxis with unfractionated heparin
(UFH) and low-molecular weight heparins such as enoxa-
parin against venous thromboembolism in acutely-ill
medical inpatients. The objective of this study was to esti-
mate the cost-effectiveness of these alternative methods of
thromboprophylaxis in this population. 
METHODS: We used techniques of decision analysis 
and data from secondary sources to estimate the cost-
effectiveness of thromboprophylaxis in acutely-ill medical
inpatients. A hypothetical cohort of 10,000 patients was
assumed to receive, alternatively, prophylaxis with: (1)
enoxaparin 40mg qd; (2) UFH 5,000IU bid; (3) UFH
5,000IU tid; or (4) no prophylaxis. For each strategy, 
we estimated the 30-day risks of thromboembolism
(deep-vein thrombosis and/or pulmonary embolism),
complications of prophylaxis and therapy (heparin-
induced thrombocytopenia and bleeding), mortality, and
costs of prophylaxis, diagnostic testing and treatment.
Cost per death averted was assessed for each method of
prophylaxis relative to no prophylaxis. A background
mortality risk of 10% was assumed.
RESULTS: In a cohort of 10,000 inpatients, expected
numbers of deaths over 30 days were 1,041 for enoxa-
parin, 1,058 for UFH bid, 1,058 for UFH tid, and 1,089
for no prophylaxis. Corresponding estimates of the
expected costs of prevention, diagnosis, and manage-
ment of venous thromboembolism were $3,655,800,
$3,750,400, $4,300,400, and $3,363,000 (2001 US$).
Relative to no prophylaxis, the cost per death averted 
was $6,101 for enoxaparin, $12,498 for UFH bid, and
$30,240 for UFH tid. Incremental analyses indicated that
prophylaxis with enoxaparin is both more effective and
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less costly than UFH. These ﬁndings were robust with
respect to changes in the background risk of throm-
boembolism and risk of death from competing causes.
CONCLUSIONS: Thromboprophylaxis with enoxaparin
represents a cost-effective use of health-care resources and
dominates strategies involving the use of UFH in acutely-
ill medical inpatients.
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OBJECTIVE: Controlled trials have demonstrated the
positive impact of statins on health outcomes in hyper-
lipidemic patients. However, few studies analyzed the
cost-effectiveness of adherence to statins. 
METHODS: Data were retrospectively gathered from a
commercial, integrated pharmacy/medical claims data-
base. Patients over 18 years with at least two statin
claims, a 120-day beneﬁt history, and a 360-day contin-
uous enrollment were selected for inclusion. Age, gender,
and concomitant drug/disease information were collected.
Adherence to statins was calculated as (total days sup-
plied)/(last claim date—ﬁrst claim date + last days
supply)*100. Total medical and drug costs, (TMDC),
including drug, hospital, physician visit and lab informa-
tion, were used to calculate per-member-per-month
(PMPM) costs during the follow-up period. Number of
patients and days to institutionalization for a disease-
related event (DRE) was determined and the costs for
DRE were calculated. ANOVA, or a non-parametric
equivalent, was used to test results across adherence 
quintiles.
RESULTS: 2317 patients (62% male) were included in
this analysis. The mean sample age was 53 with patients
taking an average of 7.1 medications concomitantly.
72.8% of patients were less than 80% adherent and
nearly 1/3 were less than 39% adherent. The median
TMDC for the sample was $379 PMPM, with costs sig-
niﬁcantly decreasing as adherence decreased (P < 0.0001).
The median cost for DRE was $313 PMPM, and also
decreased as adherence decreased, except for the >100%
adherent patients whose costs were less than the median,
though not signiﬁcantly (P = 0.703). Adherence was not
signiﬁcant in affecting the days to DRE (P = 0.4559). 
CONCLUSION: Although statins reduce cardiovascular
events over multiple years, this study conﬁrms that cost
savings cannot be expected in the ﬁrst year. If drug costs
are included in the total costs, one cannot expect an
increase in adherence to decrease the total direct health
care costs in the ﬁrst year of treatment.
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OBJECTIVE: To demonstrate differences in hospital
length-of-stay (LOS), charges, and mortality in CHF
patients by hospital and patient characteristics using 
the 1997 Hospital Cost and Utilization Project (HCUP)
database. 
METHODS: Hospitalizations with ICD-9-CM codes for
CHF were extracted from a 10% random HCUP sample
to yield 19,746 hospitalizations representing 22 states.
Hospital variables included region (Northeast, Midwest,
South, West), location (urban/rural), teaching/non-
teaching status, ownership (government, for-proﬁt, not
for-proﬁt), and hospital size (small, medium, large).
Patient variables included age (< = 50 years, 51–65 years,
>65 years), race (white, African-American, others),
gender, income (<$25,000, $25,000–$30,000, $30,000–
$35,000, >$35,000), number of comorbidities, and payer
status (Medicare, Medicaid, private/HMO, self-pay).
One-way ANOVA and chi-square statistics were used to
test for signiﬁcant (p < = 0.05) differences.
RESULTS: On average, CHF patients incurred charges of
$11,866 per hospitalization. The mean LOS per hospi-
talization was 5.83 days and the in-hospital mortality was
4.6 percent. LOS and hospital charges increased with
disease severity when patients were classiﬁed into 3 sever-
ity levels based on the number of comorbidities. Self-pay
patients had the longest LOS (8.69 days) but the lowest
charges ($11,418), and privately-insured/HMO patients
had the shortest LOS (5.33 days) but the highest charges
($13,381). For-proﬁt hospitals reported the highest mean
charges, followed by private/not proﬁt and government
hospitals. Mortality did not vary by region, location,
ownership and teaching status. Elderly patients (>65) 
had signiﬁcantly higher charges as compared to younger
patients (<50) ($ 13,817 vs. $11,607) and had higher
mortality (5.4% vs. 1.6%). High-income patients
incurred signiﬁcantly higher charges as compared to 
low-income patients ($13,456 vs. $10,840). Whites had
higher mortality (5.1%) as compared with others (4.6%)
and African-Americans (2.8%). LOS and charges did not
vary by race or gender. 
CONCLUSION: Hospital LOS, charges and mortality in
CHF patients show marked differences when compared
by patient and hospital characteristics.
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